Physician profile
Arthur E Millman
NPI 1386740231
$502.63
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $54.21 · 2021: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $110.57 | 2019 | |
| Novo Nordisk INC | $74.56 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $56.41 | 2019-2021 | |
| Amgen INC. | $56.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $55.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $35.46 | 2021 | |
| Amarin Pharma, INC. | $29.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2021 | |
| Incyte Corporation | $15.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Millman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.